Lakewood-Amedex Biotherapeutics Announces Direct Listing on Nasdaq; Shares Trading Under the Symbol "LABT"

Lakewood-Amedex Biotherapeutics Inc. has commenced trading its common stock on the Nasdaq Capital Market under the ticker symbol "LABT," marking a significant milestone for the clinical-stage biotechnology company. The announcement was made on April 23, 2026, although the specific deal value associated with the initial public offering (IPO) remains undisclosed. Lakewood-Amedex is focused on developing a novel class of antimicrobials known as Bisphosphocin®, aimed at addressing the growing threat of antibiotic-resistant infections.

Founded with the mission to combat infectious diseases, Lakewood-Amedex is pioneering the Bisphosphocin® class of compounds, which are designed to provide fast-acting and broad-spectrum antimicrobial effects. The company’s lead product, Nu-3, is being developed specifically for the topical treatment of infected diabetic foot ulcers (iDFU). The prevalence of diabetes in the United States, affecting nearly 40 million individuals, underscores the urgency of addressing complications such as diabetic foot ulcers, which can become infected in about half of all cases. This demographic presents a substantial market opportunity for Lakewood-Amedex, particularly as antibiotic resistance becomes an increasing concern in the treatment landscape.

The company plans to initiate a Phase 2a clinical trial for Nu-3 shortly, following promising results from initial exploratory clinical trials that indicated a positive antimicrobial response without safety concerns. The upcoming trials will further assess the safety and efficacy of Nu-3, as well as determine the optimal administration regimen for its gel formulation. This strategic focus on clinical development is expected to enhance the company’s position within the biotechnology sector, especially as it addresses a significant unmet medical need.

The IPO and subsequent Nasdaq listing are pivotal for Lakewood-Amedex, as they provide access to capital markets that can facilitate the accelerated development of its product pipeline. The biotechnology sector has seen increased investor interest, particularly in companies that are innovating in the field of antimicrobial resistance. As regulatory bodies and healthcare providers prioritize solutions to combat resistant infections, Lakewood-Amedex's advancements in the Bisphosphocin® class could align well with broader industry trends.

In conclusion, Lakewood-Amedex Biotherapeutics Inc.'s entry into the public market through its IPO positions the company to leverage investor interest and funding to advance its clinical programs. The growing prevalence of antibiotic-resistant infections and the increasing demand for effective treatments for diabetic foot ulcers represent significant market opportunities. As the company progresses through its clinical trials, its ability to deliver on its promises will be closely watched by investors and industry stakeholders alike, potentially influencing the broader dynamics of the biotechnology sector.